TABLE 7Continued Trial Phase Control arm Country Experimental treatment regimen(s) Experimental treatment duration, months Notes ClinicalTrials.gov identifier RIAlta 2 No Multicountry Rifampicin (35 mg·kg−1per day), isoniazid, pyrazinamide and ethambutol 6 Comparison to historical controls NCT04768231 RIFASHORT 3 Yes Multicountry Standard regimen with rifampicin at 1200 mg·day−1 or standard regimen with rifampicin at 1800 mg·day−1 4 NCT02581527 SimpliciTB 2/3 Yes Multicountry Bedaquiline, pretomanid, moxifloxacin, and pyrazinamide 4 Includes a non-randomised arm with RR-TB patients NCT03338621 TRUNCATE-TB 2/3 Yes Multicountry Isoniazid, high-dose rifampicin, pyrazinamide, ethambutol, and linezolid isoniazid, high-dose rifampicin, pyrazinamide, ethambutol, and clofazimine isoniazid, rifapentine, pyrazinamide, levofloxaxin, and linezolid bedaquiline, isoniazid, pyrazinamide, ethambutol, and linezolid 2 Multi-arm, multi-stage clinical trial NCT03474198 RR-TB ACTG A5356 2 No Multicountry Bedaquiline, clofazimine, delamanid, plus linezolid at different dosages 6 NCT05007821 BEAT Tuberculosis 3 Yes South Africa Bedaquiline, delamanid, and linezolid, plus levofloxacin or clofazimine 6 Strategy trial experimental regimen adapted according to rapid molecular testing NCT04062201 DRAMATIC 2 No Multicountry Levofloxacin, bedaquiline, linezolid, delamanid, and clofazimine 49 Duration-randomised clinical trial NCT03828201 Continued 132 https://doi.org/10.1183/2312508X.10024622 ERS MONOGRAPH |THE CHALLENGE OF TB IN THE 21ST CENTURY